Holen Sie sich die Stockscreener-App
19.28
1.15%
0.22
Vorhandelsmarkt:
19.50
0.22
+1.14%
Rigel Pharmaceuticals Aktie (RIGL) Neueste Nachrichten
Press Release Distribution & PR Platform - ACCESS Newswire
(RIGL) Trading Report - news.stocktradersdaily.com
Rigel (RIGL) Upgraded to Buy: What Does It Mean for the Stock? - Nasdaq
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - marketscreener.com
Stocks That Fell to 3-Year Lows in the Week of Sept. 13 - GuruFocus
Where are the Opportunities in (RIGL) - news.stocktradersdaily.com
Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability (RIGL) - Seeking Alpha
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
High Growth Tech Stocks in the US for April 2025 - simplywall.st
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Not Doing Enough For Some Investors As Its Shares Slump 26% - simplywall.st
Rigel settles patent litigation regarding its immune thrombocytopenia treatment - MSN
Rigel settles patent litigation over TAVALISSE treatment By Investing.com - Investing.com South Africa
Rigel Pharma stock rises on patent settlement (RIGL:NASDAQ) - Seeking Alpha
Rigel, Hetero Settle Patent Suit Over Platelet-Booster Tavalisse - Bloomberg Law News
Rigel climbs on blood disorder drug patent settlement - TradingView
Rigel settles patent litigation regarding its immune thrombocytopenia treatment (RIGL:NASDAQ) - Seeking Alpha
Rigel Pharma Settles Tavalisse Patent Litigation With Annora Pharma - Nasdaq
Rigel Pharmaceuticals Settles Patent Litigation Over Tavalisse - MarketScreener
Rigel Pharmaceuticals resolves patent litigation related to Tavalisse - TipRanks
Rigel Announces Settlement Agreement Resolving TAVALISSE® (Fostamatinib Disodium Hexahydrate) Patent Litigation - Marketscreener.com
Rigel settles patent litigation over TAVALISSE treatment - Investing.com
Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation - PR Newswire
(RIGL) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Bristol-Myers Squibb expands immuno-oncology pipeline with Flexus Biosciences, Rigel Pharmaceuticals deals - FirstWord Pharma
Rigel Pharmaceuticals appoints Mark W. Frohlich to board of directors - MSN
Statutory Profit Doesn't Reflect How Good Rigel Pharmaceuticals' (NASDAQ:RIGL) Earnings Are - Yahoo Finance
(RIGL) Investment Analysis and Advice - news.stocktradersdaily.com
Rigel Pharmaceuticals’ SWOT analysis: pipeline potential drives stock outlook - Investing.com India
Rigel Pharmaceuticals’ SWOT analysis: pipeline potential drives stock outlook By Investing.com - Investing.com South Africa
Rigel Looks Interesting, But Let's Wait For A Lower Price (NASDAQ:RIGL) - Seeking Alpha
Rigel Pharmaceuticals appoints new board member By Investing.com - Investing.com Australia
Rigel Pharmaceuticals adds oncology expert to board By Investing.com - Investing.com Australia
SEC Form 4 filed by Director Frohlich Mark W - Quantisnow
Rigel Pharmaceuticals appoints new board member - Investing.com
Rigel Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update - Quantisnow
Rigel Pharmaceuticals Appoints Dr. Frohlich to Board - TipRanks
Rigel appoints Mark W. Frohlich to its board -March 10, 2025 at 12:01 pm EDT - Marketscreener.com
Rigel Pharmaceuticals adds oncology expert to board - Investing.com India
Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors - StockTitan
Rhumbline Advisers Has $423,000 Stock Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
FY2025 EPS Estimates for RIGL Increased by Cantor Fitzgerald - Defense World
Citigroup Forecasts Strong Price Appreciation for Rigel Pharmaceuticals (NASDAQ:RIGL) Stock - Defense World
Rigel Pharmaceuticals Implements 1-for-10 Reverse Stock Split: Balancing Nasdaq Compliance and Investor Appeal - MSN
Rigel Pharmaceuticals (NASDAQ:RIGL) Downgraded by StockNews.com to “Buy” - Defense World
What is B. Riley’s Forecast for RIGL Q1 Earnings? - Defense World
What is HC Wainwright’s Estimate for RIGL Q1 Earnings? - Defense World
Earnings call transcript: Rigel Pharmaceuticals Q4 2024 sees strong growth By Investing.com - Investing.com Australia
Rigel Pharmaceuticals, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Yahoo Finance
Rigel Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
B. Riley Forecasts Strong Price Appreciation for Rigel Pharmaceuticals (NASDAQ:RIGL) Stock - Defense World
HC Wainwright Reiterates Buy Rating for Rigel Pharmaceuticals (NASDAQ:RIGL) - Defense World
What is B. Riley’s Estimate for RIGL FY2026 Earnings? - Defense World
Q3 Earnings Forecast for RIGL Issued By HC Wainwright - Defense World
0.24%
36.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):